Fisher & Paykel Healthcare traded at 39.60 this Monday October 26th, decreasing 0.08 or 0.20 percent since the previous trading session. Looking back, over the last four weeks, Fisher & Paykel Healthcare lost 8.61 percent. Over the last 12 months, its price rose by 28.61 percent. Looking ahead, we forecast Fisher & Paykel Healthcare to be priced at 38.93 by the end of this quarter and at 36.75 in one year, according to Trading Economics global macro models projections and analysts expectations.
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The Company’s segment includes North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, and Other segment includes New Zealand, Latin America, Africa, the Middle East and other countries.